Compare KREF & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | ORGO |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.9M | 539.1M |
| IPO Year | 2017 | N/A |
| Metric | KREF | ORGO |
|---|---|---|
| Price | $8.44 | $4.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $10.71 | $8.00 |
| AVG Volume (30 Days) | 843.1K | ★ 3.1M |
| Earning Date | 10-21-2025 | 11-06-2025 |
| Dividend Yield | ★ 11.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $62,012,000.00 | ★ $465,218,000.00 |
| Revenue This Year | $16.86 | $8.14 |
| Revenue Next Year | N/A | $6.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.24 |
| 52 Week Low | $7.78 | $2.61 |
| 52 Week High | $11.74 | $7.08 |
| Indicator | KREF | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 46.12 |
| Support Level | $8.38 | $4.87 |
| Resistance Level | $8.63 | $5.83 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 70.34 | 3.38 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.